-
Clinical Trials & Development1 month agoFDA launches pilot program to speed up sluggish phase 1 trials
After teasing a new initiative to speed up early-stage clinical trials over the summer, the FDA today opened a pilot program for an expedited investigational new...
-
Clinical Trials & Development1 month agoSTAT+: Vera kidney drug Trutakna shows strong final results in Phase 3 trial
The drug stabilized kidney function and reduced the risk of death and other complications in IgAN patients
-
Clinical Trials & Development1 month ago
Connect’s Dupixent rival flunks phase 2 asthma trial, but biotech sees reasons for hope
Connect Biopharma’s hopes of dethroning Dupixent took a knock as its IL-4/IL-13 blocker missed the primary endpoint of a phase 2 asthma study.
-
Clinical Trials & Development1 month agoWCLC: Lung cancer news from BioNTech, Akeso, and Roche
As the World Conference on Lung Cancer (WCLC) draws to a close, here are some late-breaking clinical trial data that made waves at the congress.
-
Clinical Trials & Development1 month ago
GSK doubles down on Chimagen with $750M multiple myeloma wager
GSK has bet up to $750 million on a Chimagen Biosciences trispecific T-cell engager, positioning the Big Pharma to start phase 1 development of the multiple...
-
Clinical Trials & Development1 month ago
J&J’s Contineum-partnered depression drug flunks another phase 2 test
A phase 2 trial of Johnson & Johnson’s JNJ-5120 has missed its primary endpoint, denting the prospects of the Contineum Therapeutics-partnered depression drug candidate.
-
Clinical Trials & Development1 month agoSummit, Akeso look to shed PD-1/VEGF drug doubts with latest study results
As dueling data emerge between their drug ivonescimab and a rival Merck medication, Summit and Akeso revealed new findings that impressed Wall Street.
-
Clinical Trials & Development1 month ago
Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity
NORWOOD, Mass., September 14, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today...
-
Clinical Trials & Development1 month agoWhy Does a Particular Genetic Variant Lead to Accelerated Huntington Disease Development?
Study results suggest how a particular genetic variant can speed onset of Huntington disease motor symptoms by up to 12.5 years and accelerate clinical measures of...
-
Clinical Trials & Development1 month ago
Clinical trials reach a new automation inflection point
As trial complexity grows, agentic AI is emerging as a new model for connecting workflows and accelerating execution.
Genmab’s cancer bispecific delivers early survival win in ‘exceedingly positive’ Phase 3 readout
Genmab’s cancer bispecific delivers early OS win in ‘exceedingly positive’ Phase 3 readout
STAT+: HHS moves to allow compounding of some unapproved peptides
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
